<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828191</url>
  </required_header>
  <id_info>
    <org_study_id>07USA/Prg05</org_study_id>
    <nct_id>NCT00828191</nct_id>
  </id_info>
  <brief_title>Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)</brief_title>
  <official_title>Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) Versus Vaginal Progesterone for Luteal Phase Support in Patients Undergoing In Vitro Fertilization (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open, randomized, parallel, multicenter, two-arm trial to evaluate the efficacy
      and tolerability of a new progesterone formulation to be used for luteal support in IVF
      (Progesterone-IBSA) administered subcutaneously at a daily dose of 25 mg versus Progesterone
      tablets administered intravaginally at 100 mg twice daily for a total dose of 200 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ongoing Pregnancy Rate</measure>
    <time_frame>10 weeks after treatment start</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation Rate</measure>
    <time_frame>4-5 weeks after treatment start</time_frame>
    <safety_issue>No</safety_issue>
    <description>Implantation rate was defined as the number of gestational sacs divided by the number of embryos transferred (%). This value was calculated for all the patients who had at least one embryo transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivery Rate</measure>
    <time_frame>nearly 9 months after treatment start</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>In Vitro Fertilization</condition>
  <arm_group>
    <arm_group_label>Progesterone SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>25 mg, once a day, SC</description>
    <arm_group_label>Progesterone SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>100 mg, twice a day, vaginally</description>
    <arm_group_label>Progesterone Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has given written informed consent;

          -  BMI &lt; 30 kg/m2;

          -  Age 18 - 42 (upon starting COH);

          -  &lt;3 prior ART cycles (IVF, ICSI and related procedures);

          -  Baseline (day 2-3 of cycling) FSH &lt;15 IU/L and E2 &lt;80 pg/mL;

          -  Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or
             hysteroscopic exam (i.e. no polyps or protruding submucosal fibroids);

          -  Patients must have at least three retrieved oocytes.

        Exclusion Criteria:

          -  Intramural uterine fibroids that distort the uterine cavity or polyps &gt;1 cm;

          -  Stage III or IV endometriosis (no endometriomas);

          -  Hydrosalpinges;

          -  History of past poor response to COH resulting in canceling ART;

          -  Use of thawed/donated oocytes;

          -  Use of thawed/donated embryos;

          -  Gestational carrier;

          -  Patients affected by pathologies associated with any contraindication of being
             pregnant;

          -  Hypersensitivity to study medication;

          -  Uncontrolled adrenal or thyroid dysfunction;

          -  History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a
             vaginal progesterone product;

          -  History of arterial disease;

          -  Patients with hepatic impairment (liver function tests &gt; 2x upper limits of normal);

          -  Patients with dermatologic disease;

          -  Patients with renal impairment (estimated creatinine clearance &lt;60 mL/min/1.73 m2);

          -  Neoplasias (current) or history of neoplasia that may be responsive to progesterone;

          -  High grade cervical dysplasia;

          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages,
             wherein pregnancy developed to a minimum of a gestational sac on TVUS;

          -  Participation in a concurrent clinical trial or in another trial within the past 2
             months;

          -  Use of concomitant medications that might interfere with the study evaluation;

          -  Pre-implantation genetic diagnosis/screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive Partners Medical Group, Inc.</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Physicians of Northern California</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility and Surgical Associates of California</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reproductive Medicine</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Center for Reproductive Medicine</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Assisted Reproduction</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Reproductive Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 28, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2009</firstreceived_date>
  <firstreceived_results_date>November 26, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Luteal support in IVF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Progesterone SC</title>
          <description>Progesterone SC given at a daily dose of 25 mg.</description>
        </group>
        <group group_id="P2">
          <title>Progesterone Tablets</title>
          <description>Progesterone vaginal tables 100 mg given twice à day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="400">Randomized patients</participants>
                <participants group_id="P2" count="400">Randomized patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="392">Patients with at least one embryo transferred.</participants>
                <participants group_id="P2" count="390">Patients with at least one embryo transferred.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Progesterone SC</title>
          <description>Progesterone SC given at a daily dose of 25 mg.</description>
        </group>
        <group group_id="B2">
          <title>Progesterone Tablets</title>
          <description>Progesterone vaginal tables 100 mg given twice à day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="400"/>
                <measurement group_id="B2" value="400"/>
                <measurement group_id="B3" value="800"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="400"/>
                <measurement group_id="B2" value="400"/>
                <measurement group_id="B3" value="800"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34.3" spread="4.4"/>
                <measurement group_id="B2" value="34.3" spread="4.5"/>
                <measurement group_id="B3" value="34.3" spread="4.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="400"/>
                <measurement group_id="B2" value="400"/>
                <measurement group_id="B3" value="800"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="400"/>
                <measurement group_id="B2" value="400"/>
                <measurement group_id="B3" value="800"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ongoing Pregnancy Rate</title>
        <time_frame>10 weeks after treatment start</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized patients were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone SC</title>
            <description>Progesterone SC given at a daily dose of 25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Progesterone Tablets</title>
            <description>Progesterone vaginal tables 100 mg given twice à day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="400"/>
                  <measurement group_id="O2" value="400"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ongoing Pregnancy Rate</title>
            <units>percentage of randomized patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40.8"/>
                  <measurement group_id="O2" value="43.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The non -inferiority hypothesis to be tested for the primary endpoint was that the ongoing pregnancy rate (oPR) in the test group (Pe)was lower than the oPR in the control group (Pc)against the alternative one that the oPR in the test group was equal to or higher than the oPR in the control group.
H0 : Pc&gt;= Pe + d(-10%) H1 : Pc&lt; Pe + d(-10%)</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The null hypothesis (H0) was tested against the alternative by calculating a two-sided 95% confidence interval for the difference in ongoing pregnancy rates. If the lower bound of the 95% confidence interval was greater than the non-inferiority limit (-10.0%), the null hypothesis was rejected and the test group considered not inferior to the control treatment.</non_inferiority_desc>
            <p_value>0.52</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in pregnancy rates</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.4</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implantation Rate</title>
        <description>Implantation rate was defined as the number of gestational sacs divided by the number of embryos transferred (%). This value was calculated for all the patients who had at least one embryo transferred.</description>
        <time_frame>4-5 weeks after treatment start</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patient who had at least one embryo transferred.</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone SC</title>
            <description>Progesterone SC given at a daily dose of 25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Progesterone Tablets</title>
            <description>Progesterone vaginal tables 100 mg given twice à day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="392"/>
                  <measurement group_id="O2" value="390"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Implantation Rate</title>
            <description>Implantation rate was defined as the number of gestational sacs divided by the number of embryos transferred (%). This value was calculated for all the patients who had at least one embryo transferred.</description>
            <units>percentage of embryos transferred</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33.2" spread="42.0"/>
                  <measurement group_id="O2" value="35.1" spread="40.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.54</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delivery Rate</title>
        <time_frame>nearly 9 months after treatment start</time_frame>
        <safety_issue>No</safety_issue>
        <population>All randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Progesterone SC</title>
            <description>Progesterone SC given at a daily dose of 25 mg.</description>
          </group>
          <group group_id="O2">
            <title>Progesterone Tablets</title>
            <description>Progesterone vaginal tables 100 mg given twice à day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="400"/>
                  <measurement group_id="O2" value="400"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Delivery Rate</title>
            <units>percentage of randomized patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40.5"/>
                  <measurement group_id="O2" value="42.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.62</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>None of the patients reported SAE considered as related to study drugs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Progesterone SC</title>
          <description>Progesterone SC given at a daily dose of 25 mg.</description>
        </group>
        <group group_id="E2">
          <title>Progesterone Tablets</title>
          <description>Progesterone vaginal tables 100 mg given twice à day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="400"/>
                <counts group_id="E2" events="35" subjects_affected="28" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="400"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="38" subjects_affected="37" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" events="68" subjects_affected="57" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <description>AE associated with vaginal administration</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="400"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain/tenderness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="400"/>
                <counts group_id="E2" events="44" subjects_affected="42" subjects_at_risk="400"/>
              </event>
              <event>
                <sub_title>vaginal hemorrage</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="400"/>
                <counts group_id="E2" events="34" subjects_affected="30" subjects_at_risk="400"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations of the trial reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>IBSA U.S. Agent</name_or_title>
      <organization>IBSA Institut Biochimique SA</organization>
      <phone>805 376 00 78</phone>
      <email>cejtwsxx@verizon.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
